Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 beta-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p- isothiocyanatophenylethyl ester hydrochloride]

AE Fleckenstein, S Pogun, FI Carroll and MJ Kuhar

National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.

Effects of in vivo, intrastriatal administration of RTI-76 3 beta-(3-p- chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanato- phenylethyl ester hydrochloride, an irreversible inhibitor of dopamine transporter (DAT) binding in vitro, on [125I]RTI-55 3 beta-[4- iodophenyl]tropan-2 beta-carboxylic acid methyl ester tartrate binding to striatal DAT in vitro were examined in male rats. Effects on [3H]DAT and D1 dopamine receptor binding in vitro after intrastriatal RTI-76 injection were also determined. One hour after direct intrastriatal injection, RTI-76 caused a dose-related increase in KD for [125I]RTI-55 binding in vitro in striatal tissue, without affecting transporter maximum binding (Bmax). In contrast, 24 hr after administration, RTI-76 caused a dose-related decrease in striatal DAT Bmax without affecting KD, a decrease that reversed over the next several days. Transport of [3H]dopamine into synaptosomes was decreased similarly. Intrastriatal injection of reversible inhibitors of DAT, such as cocaine or WIN-35428 3 beta-[4-fluorophenyl]tropan-2 beta-carboxylic acid methyl ester tartrate), was without effect on transporter binding 1 and 6 days after administration. RTI-76 had little effect on [3H]SCH-23390 R-(+)-7- chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine binding 1 or 24 hr after intrastriatal injection, indicating at least some selectivity of RTI-76 for DAT. The RTI-76-induced decrease in Bmax, as well as the concurrent decrease in [3H]DAT, were reversible, with the T1/2 of transporter recovery estimated to be 6 days.

Volume 279, Issue 1, pp. 200-206, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				V. Murthy, T. J. Martin, S. Kim, H. M. L. Davies, and S. R. Childers In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 587 - 595. [Abstract] [Full Text] [PDF]

				D. R. Thakker, F. Natt, D. Husken, R. Maier, M. Muller, H. van der Putten, D. Hoyer, and J. F. Cryan Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference PNAS, December 7, 2004; 101(49): 17270 - 17275. [Abstract] [Full Text] [PDF]

				J. A. Moron, I. Zakharova, J. V. Ferrer, G. A. Merrill, B. Hope, E. M. Lafer, Z. C. Lin, J. B. Wang, J. A. Javitch, A. Galli, et al. Mitogen-Activated Protein Kinase Regulates Dopamine Transporter Surface Expression and Dopamine Transport Capacity J. Neurosci., September 17, 2003; 23(24): 8480 - 8488. [Abstract] [Full Text] [PDF]

				V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1181 - 1187. [Abstract] [Full Text] [PDF]

				H. L. Kimmel, F. I. Carroll, and M. J. Kuhar Withdrawal from Repeated Cocaine Alters Dopamine Transporter Protein Turnover in the Rat Striatum J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 15 - 21. [Abstract] [Full Text] [PDF]

				V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors J. Neurosci., October 1, 2002; 22(19): 8705 - 8710. [Abstract] [Full Text] [PDF]

				Q. Wu, M. E. A. Reith, Q. D. Walker, C. M. Kuhn, F. I. Carroll, and P. A. Garris Concurrent Autoreceptor-Mediated Control of Dopamine Release and Uptake during Neurotransmission: An In Vivo Voltammetric Study J. Neurosci., July 15, 2002; 22(14): 6272 - 6281. [Abstract] [Full Text] [PDF]

				Q. Wu, M. E. A. Reith, M. J. Kuhar, F. I. Carroll, and P. A. Garris Preferential Increases in Nucleus Accumbens Dopamine after Systemic Cocaine Administration Are Caused by Unique Characteristics of Dopamine Neurotransmission J. Neurosci., August 15, 2001; 21(16): 6338 - 6347. [Abstract] [Full Text] [PDF]

				H. L. Kimmel, A. R. Joyce, F. I. Carroll, and M. J. Kuhar Dopamine D1 and D2 Receptors Influence Dopamine Transporter Synthesis and Degradation in the Rat J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 129 - 140. [Abstract] [Full Text]

				A. L. Bauman, S. Apparsundaram, S. Ramamoorthy, B. E. Wadzinski, R. A. Vaughan, and R. D. Blakely Cocaine and Antidepressant-Sensitive Biogenic Amine Transporters Exist in Regulated Complexes with Protein Phosphatase 2A J. Neurosci., October 15, 2000; 20(20): 7571 - 7578. [Abstract] [Full Text] [PDF]

				J. B. Daunais, S. L. Hart, H. R. Smith, S. R. Letchworth, H. M. L. Davies, T. Sexton, B.A. Bennett, S. R. Childers, and L. J. Porrino Long-Acting Blockade of Biogenic Amine Transporters in Rat Brain by Administration of the Potent Novel Tropane 2beta -Propanoyl-3beta -(2-Naphthyl)-Tropane J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1246 - 1254. [Abstract] [Full Text] [PDF]

				S. Ramamoorthy, E. Giovanetti, Y. Qian, and R. D. Blakely Phosphorylation and Regulation of Antidepressant-sensitive Serotonin Transporters J. Biol. Chem., January 23, 1998; 273(4): 2458 - 2466. [Abstract] [Full Text] [PDF]

				A. E. Fleckenstein, R. R. Metzger, D. G. Wilkins, J. W. Gibb, and G. R. Hanson Rapid and Reversible Effects of Methamphetamine on Dopamine Transporters J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 834 - 838. [Abstract] [Full Text]